A technically dense, data-grounded analysis of repurposing economics, IP valuation, regulatory pathways, computational platforms, and lifecycle management tactics for existing […]
Drug Repurposing: The Definitive Strategic Guide Read Post »
Why Patents Are the Wrong Starting Point Most analysts open a pharma investment thesis by pulling Orange Book listings and
What Actually Drives Pharma Returns: 10 Non-Patent Factors Every Investor Needs to Model Read Post »
1. Executive Summary FDA approval of a generic drug is a regulatory milestone, not a commercial launch date. The gap
Part I: US Pharmaceutical Market — Scale, Structural Drivers, and the 2025 Inflection Point Market Size Reality Check: Reconciling Competing
Get fresh news and insights, drug patent expirations & more…
